Cargando…
Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation
Autores principales: | Ainley, Louise, Law, Steven, Heptinstall, Lauren, Rodriguez-Justo, Manuel, Thomson, Kirsty, Pepper, Ruth J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783564/ https://www.ncbi.nlm.nih.gov/pubmed/33426402 http://dx.doi.org/10.1016/j.ekir.2020.10.012 |
Ejemplares similares
-
Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis
por: Alabdaljabar, Mohamad S., et al.
Publicado: (2020) -
NELL1-Associated Membranous Glomerulopathy After Hematopoietic Stem Cell Transplantation
por: Kudose, Satoru, et al.
Publicado: (2021) -
Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation
por: Sy-Go, Janina Paula T., et al.
Publicado: (2020) -
Membranous Glomerulopathy After Autologous Hematopoietic Stem Cell Transplant in a Patient With Multiple Myeloma
por: Rodríguez Feria, Daniela, et al.
Publicado: (2021) -
Epstein Barr Virus–Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease
por: D’Costa, Matthew R., et al.
Publicado: (2021)